Savara’s (SVRA) “Market Outperform” Rating Reaffirmed at JMP Securities

JMP Securities restated their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report report published on Tuesday, Benzinga reports. The firm currently has a $9.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Savara in a report on Tuesday. Oppenheimer upped their price target on Savara from $11.00 to $15.00 and gave the company an outperform rating in a research note on Wednesday, June 26th. Finally, Guggenheim lifted their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average target price of $11.17.

Savara Price Performance

Shares of SVRA stock opened at $3.81 on Tuesday. Savara has a 12 month low of $3.12 and a 12 month high of $5.70. The stock has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.44. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $526.50 million, a price-to-earnings ratio of -10.30 and a beta of 0.97.

Savara (NASDAQ:SVRA) last released its earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts expect that Savara will post -0.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Bain Capital Life Sciences Investors LLC raised its position in Savara by 2.3% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after buying an additional 332,706 shares during the last quarter. Jennison Associates LLC increased its position in shares of Savara by 0.3% during the 1st quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock worth $44,033,000 after purchasing an additional 26,613 shares during the last quarter. Frazier Life Sciences Management L.P. raised its stake in shares of Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its stake in shares of Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.